ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
lorlatinib Sensitive: A2 - Guideline
|
lorlatinib Sensitive: A2 - Guideline
|
ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
alectinib Resistant: C3 – Early Trials
|
alectinib Resistant: C3 – Early Trials
|
ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
ensartinib Resistant: C3 – Early Trials
|
ensartinib Resistant: C3 – Early Trials
|
ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
ceritinib Resistant: C3 – Early Trials
|
ceritinib Resistant: C3 – Early Trials
|
ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
crizotinib Resistant: C3 – Early Trials
|
crizotinib Resistant: C3 – Early Trials
|
ALK G1202R
|
NSCLC
|
ALK G1202R
|
NSCLC
|
brigatinib Sensitive: C4 – Case Studies
|
brigatinib Sensitive: C4 – Case Studies
|